Related Experiment Video
Updated: Jul 4, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Targeting Androgen Receptor Mutations in Metastatic Castration-Resistant Prostate Cancer with a Novel Androgen
1Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.
Abstract:
Multiple therapeutic advances in recent years have significantly improved outcomes for patients with metastatic prostate cancer, including utilization of combination androgen receptor (AR) pathway inhibitors and/or taxane chemotherapy in earlier, hormone-sensitive disease.1 Unfortunately, patients typically still develop metastatic castration-resistant prostate cancer (mCRPC), the lethal form of disease with limited prognosis. Despite castration resistance, the majority of patients with mCRPC continue to have AR-dependent disease through a variety of mechanisms, including emergence of AR mutations, amplifications, splice variants, and persistent AR activation via alternative pathways of androgen production.2.
Insights
New treatments improve outcomes for metastatic prostate cancer. However, most patients develop lethal castration-resistant prostate cancer, which remains dependent on the androgen receptor (AR) pathway.
Area of Science:
- Oncology
- Urology
Background:
- Recent advances include combination androgen receptor (AR) pathway inhibitors and taxane chemotherapy for hormone-sensitive metastatic prostate cancer.
- Despite these advances, patients frequently progress to metastatic castration-resistant prostate cancer (mCRPC), a lethal stage with poor prognosis.
Discussion:
- The majority of mCRPC cases remain dependent on the AR pathway.
- Mechanisms of continued AR dependence include AR mutations, amplifications, splice variants, and alternative androgen production pathways.
Key Insights:
- Therapeutic strategies for metastatic prostate cancer have advanced, improving early-stage outcomes.
- Metastatic castration-resistant prostate cancer (mCRPC) remains a significant clinical challenge.
- Androgen receptor (AR) pathway signaling persists in most mCRPC cases, offering therapeutic targets.
Outlook:
- Further research into AR-dependent mechanisms in mCRPC is crucial.
- Developing novel therapies targeting AR pathway alterations in mCRPC is a priority.
- Combination therapies may overcome resistance mechanisms in advanced prostate cancer.
